title: Prospective evaluation of quality of life (SF-36v2) and nonspecific symptoms before and after cure of primary hyperparathyroidism (1-year follow-up).
abstract: BACKGROUND
  Only a minority of patients with primary hyperparathyroidism (pHPT) present with the "classic" symptoms. Most patients have numerous nonspecific symptoms. The aim of this study was to evaluate patients' quality of life and nonspecific symptoms before and after cure for pHPT.
  
  
  METHODS
  This prospective, multicentric study, which took place from May 2003 to September 2004, included 100 patients. Six academic departments of Endocrine Surgery in France participated in the study: the University of Angers, Limoges, Nancy, Nantes, Marseille, and Poitiers. Only cured patients were included. All patients were given preoperative and postoperative questionnaires (the SF-36v2 Health Survey) at 3, 6, and 12 months to evaluate quality of life and nonspecific symptoms.
  
  
  RESULTS
  Preoperatively, the main nonspecific symptoms included the following: anxiety (89%); muscular, bone, or join pain (87%); abdominal distention (82%); forgetfulness (81%); headaches (81%); and mood swings (79%). Quality of life was significantly improved at 3 and 6 months (P < .05). At 1 year postoperatively, statistically significant improvement (P < .05) persisted in all 8 domains of the SF-36v2. At 1 year after parathyroidectomy, 5 symptoms remained significantly improved: appetite loss, weight loss, thirst, headache, and nausea.
  
  
  CONCLUSIONS
  Operative cure of primary hyperparathyroidism significantly improves quality of life and nonspecific symptoms for at least 1 year.
authors.affiliation: Department of Digestive and Endocrine Surgery, CHU Nantes, France.
authors.forename: Cécile
authors.initials: C
authors.lastname: Caillard
authors.forename: Frédéric
authors.initials: F
authors.lastname: Sebag
authors.forename: Muriel
authors.initials: M
authors.lastname: Mathonnet
authors.forename: Hélène
authors.initials: H
authors.lastname: Gibelin
authors.forename: Laurent
authors.initials: L
authors.lastname: Brunaud
authors.forename: Coralie
authors.initials: C
authors.lastname: Loudot
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Kraimps
authors.forename: Antoine
authors.initials: A
authors.lastname: Hamy
authors.forename: Laurent
authors.initials: L
authors.lastname: Bresler
authors.forename: Bernard
authors.initials: B
authors.lastname: Charbonnel
authors.forename: Joel
authors.initials: J
authors.lastname: Leborgne
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Henry
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Nguyen
authors.forename: Eric
authors.initials: E
authors.lastname: Mirallié
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006305:Health Status Indicators; D006801:Humans; D049950:Hyperparathyroidism, Primary / Q000503:physiopathology* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D016105:Parathyroidectomy; D011446:Prospective Studies; D011788:Quality of Life; D016896:Treatment Outcome